Search alternatives:
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
linear decrease » linear increase (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
_ patient » _ patients (Expand Search)
Showing 1 - 20 results of 15,943 for search '(((( a ((e decrease) OR (mean decrease)) ) OR ( _ patient decrease ))) OR ( _ linear decrease ))', query time: 0.77s Refine Results
  1. 1
    Maximum IFN concentrations are decreased in severe patients.

    Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Loss of Vps34 is associated with decreased eTreg survival but intact activation.

    Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Experimental validation revealed that ACADSB and ACADM decreased in patients with UC.

    Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Baseline patient characteristics.

    Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    <i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages.

    <i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

    Published 2024
    Save to List
    Saved in:
  7. 7
    Linear regression analysis.

    Linear regression analysis. by Young Kyu Lee (14076058)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Naringenin decreases mitochondrial function.

    Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

    Published 2025
    Save to List
    Saved in:
  11. 11
    MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation.

    MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

    Published 2024
    Save to List
    Saved in:
  12. 12
    Naringenin decreases total cell viability.

    Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Flow chart of the study participants.

    Flow chart of the study participants. by Oscar F. C. van den Bosch (22184246)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs.

    Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

    Published 2025
    Save to List
    Saved in:
  17. 17
    S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital

    S2 File - Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital by Sonsawan Sangprasert (22772538)

    Published 2025
    “…S2 File - <p>Factors influencing effective decrease of controlled attenuation parameters in metabolic-associated steatotic liver disease: A multilevel linear regression analysis at Vajira Hospital</p>…”
    Save to List
    Saved in:
  18. 18
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: